Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Draft GL on Use, Management of Thalidomide
October 6, 2003
- WORLD NEWS IN BRIEF
October 6, 2003
- REGULATORY NEWS IN BRIEF
October 6, 2003
- Pharma Delegates to Welcome Presidents from Japanese Firms: Chairman Yamasaki
October 6, 2003
- BULLETIN
October 6, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 29, 2003
- NEW PRODUCTS
September 29, 2003
- Nihon Schering Establishing New Research Center in Kobe
September 29, 2003
- Meet the Leaders (25)
September 29, 2003
- Kurume Univ. to Begin Course in Biostatistics
September 29, 2003
- WORLD NEWS IN BRIEF
September 29, 2003
- PRESS SEMINAR
September 29, 2003
- Boosting Awareness of Migraine Key to Maxalt Promotion: Eisai
September 29, 2003
- JACDS Proposes OTC Drug Reclassification for Sales Deregulation
September 29, 2003
- Banyu to Provide Tailor-made Evidence to Boost Nu-lotan
September 29, 2003
- Free OTC Drugs Supply via Videophone Violates PAL?
September 29, 2003
- Sales of Uralyt Could Triple to \10 Bil.: Nippon Chemiphar
September 29, 2003
- OTC NEWS IN BRIEF
September 29, 2003
- Mochida to Transfer All Ethical Drug Formulation to Otawara Plant
September 29, 2003
- MEDICAL DEVICE NEWS IN BRIEF
September 29, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…